Bridge to Life Showcases Innovations in Liver Transplantation
Bridge to Life Showcases Innovations in Liver Transplantation
Bridge to Life™ Ltd, a frontrunner in organ preservation and perfusion technology, is excited to announce its participation in the prestigious International Congress of the International Liver Transplantation Society (ILTS). This annual conference is set to occur in Singapore from May 28 to May 31, 2025. The event will feature the presentation of nine notable abstracts, among which are two critical late-breaker studies focusing on the application of hypothermic oxygenated perfusion (HOPE) in liver transplants, including unique contributions aimed at pediatric patients.
Highlighted Abstracts on Hypothermic Oxygenated Perfusion
Among the highlights of the conference, the late-breaker presentation titled Impact of Machine Perfusion on Ischemia-Reperfusion Injury in Liver Transplantation: A Donor Age-Stratified Analysis is anticipated to take center stage. This research examines the implications of machine perfusion technology across different donor age groups and sets a foundation for improving transplant outcomes.
Another significant late-breaker presentation is Machine Perfusion in Liver Transplantation: A Game Changer for Middle-Volume Centers? This study investigates the potential transformational effects of machine perfusion in institutions with moderate transplant volume, providing insights that could reshape practices in the field.
Expanding the Scope of HOPE in Transplantation
The contributions to the framework of HOPE continue with the abstract titled Use of HOPE Machine Perfusion for Transplantation in Unusual Scenarios - A Case Report. This report illustrates novel case applications of HOPE technology, demonstrating its flexibility and adaptability across various transplantation situations. Further presentations will delve into pediatric applications, with findings from Hypothermic Oxygenated Perfusion (HOPE) in Pediatric Liver Transplantation: Preliminary Results. This will provide vital early findings shedding light on outcomes in younger patients receiving liver transplants.
Additionally, the research HOPE for Hepatocellular Carcinoma - Recurrence Analysis in Patients Transplanted with Grafts Submitted to Hypothermic Oxygenated Perfusion will analyze cancer recurrence rates in patients, offering potential pathways for better management and outcomes in this challenging demographic.
Connecting with the Community Through Workshops and Symposiums
Bridge to Life is not only focused on presenting research but is also committed to sharing knowledge and practical skills through participation in the Hands-On Liver Machine Perfusion Workshop on May 28, 2025. This workshop serves as an essential learning platform, allowing professionals to gain hands-on experience with advanced perfusion technologies.
Moreover, Bridge to Life will sponsor an impactful symposium on May 29, at 3:00 PM SST (UTC+8), titled Expanding the Boundaries of Hypothermic Oxygenated Perfusion: Addressing Challenges and Opportunities in the Asia-Pacific Region. Esteemed speakers, such as Dr. Sonal Asthana from Aster Hospitals and Dr. Rebeca Sanabria Mateos from Queen Elizabeth Hospital, will share critical insights and strategies for overcoming hurdles in transplant care and enhancing patient outcomes.
About Bridge to Life Ltd
Bridge to Life™ Ltd is recognized globally for its pioneering contributions to organ preservation solutions. The company is known for premier products like Belzer UW, EasiSlush, and the VitaSmart™ Hypothermic Oxygenated Perfusion System, each developed with unwavering commitment to quality and patient safety. By actively collaborating with leading transplant centers and organ procurement organizations, Bridge to Life strives to ensure accessible and innovative care for patients in need of organ transplants.
In conclusion, the anticipated presentations at the ILTS congress highlight important advancements within the field, particularly surrounding the application of HOPE in liver transplants. By sharing research and knowledge, Bridge to Life aims to contribute significantly to the evolving landscape of transplantation.
Frequently Asked Questions
What is the purpose of the ILTS congress?
The ILTS congress aims to bring together leading professionals in liver transplantation to share research, advancements, and best practices to improve patient care.
What does HOPE stand for in liver transplantation?
HOPE stands for Hypothermic Oxygenated Perfusion, a technique used to preserve liver organs before transplantation, enhancing their viability and function.
Who will be presenting at the symposium hosted by Bridge to Life?
The symposium will feature notable professionals, including Dr. Sonal Asthana and Dr. Rebeca Sanabria Mateos, who will discuss challenges and advancements in liver transplantation.
How can professionals attend the Hands-On Workshop?
Professionals interested in attending the Hands-On Liver Machine Perfusion Workshop must register separately to participate in this unique educational opportunity.
What products does Bridge to Life offer for organ preservation?
Bridge to Life offers innovative products like Belzer UW, EasiSlush, and the VitaSmart system, aimed at improving organ preservation and transplantation outcomes.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
